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Abstract
Background: It is uncertain to what extent oral supplementation with zinc can reduce episodes of malaria in endemic areas.
Protection may depend on other nutrients. We measured the effect of supplementation with zinc and other nutrients on
malaria rates.
Methods and Findings: In a 262 factorial trial, 612 rural Tanzanian children aged 6–60 months in an area with intense
malaria transmission and with height-for-age z-score#21.5 SD were randomized to receive daily oral supplementation with
either zinc alone (10 mg), multi-nutrients without zinc, multi-nutrients with zinc, or placebo. Intervention group was
indicated by colour code, but neither participants, researchers, nor field staff knew who received what intervention. Those
with Plasmodium infection at baseline were treated with artemether-lumefantrine. The primary outcome, an episode of
malaria, was assessed among children reported sick at a primary care clinic, and pre-defined as current Plasmodium infection
with an inflammatory response, shown by axillary temperature $37.5uC or whole blood C-reactive protein concentration
$8 mg/L. Nutritional indicators were assessed at baseline and at 251 days (median; 95% reference range: 191–296 days). In
the primary intention-to-treat analysis, we adjusted for pre-specified baseline factors, using Cox regression models that
accounted for multiple episodes per child. 592 children completed the study. The primary analysis included 1,572 malaria
episodes during 526 child-years of observation (median follow-up: 331 days). Malaria incidence in groups receiving zinc,
multi-nutrients without zinc, multi-nutrients with zinc and placebo was 2.89/child-year, 2.95/child-year, 3.26/child-year, and
2.87/child-year, respectively. There was no evidence that multi-nutrients influenced the effect of zinc (or vice versa). Neither
zinc nor multi-nutrients influenced malaria rates (marginal analysis; adjusted HR, 95% CI: 1.04, 0.93–1.18 and 1.10, 0.97–1.24
respectively). The prevalence of zinc deficiency (plasma zinc concentration ,9.9 mmol/L) was high at baseline (67% overall;
60% in those without inflammation) and strongly reduced by zinc supplementation.
Conclusions: We found no evidence from this trial that zinc supplementation protected against malaria.
Trial Registration: ClinicalTrials.gov NCT00623857
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Introduction
Preventive zinc supplementation among children in low-income
countries can reduce the burden of diarrhoea and respiratory tract
infections [1]. If effective against malaria, it would be an important
advance in public health, particularly in Africa, where 90% of
malarial deaths occur. Anti-malarial efficacy of zinc supplemen-
tation has thus far been investigated in four trials of which we are
aware, with discordant results. In one trial in Gambian children,
twice-weekly zinc seemed to reduce the mean number of clinic
visits for malaria by 32% [2], but this trial was not designed to
evaluate protection from malaria, and the statistical evidence was
weak. In another trial in Papua New Guinean children, daily zinc
reduced rates of malaria due to Plasmodium falciparum by 38% [3].
By contrast, in trials in Burkina Faso and Peru [4,5], there was no
evidence of protection against malaria in the children enrolled,
despite zinc deficiency being highly prevalent at baseline and
reversed by supplementation.
In these trials, malaria was detected among children self-
reporting at clinics in Papua New Guinea and The Gambia,
whereas cases were detected through regular home visits in
Burkina Faso and Peru. This could indicate that zinc supplemen-
tation is more efficacious in preventing severe malaria than mild
episodes, for which mothers do not immediately seek treatment.
Alternatively, the response to zinc may be suppressed when
children are also deficient in other nutrients [6,7]. Simultaneous
supplementation with other nutrients may be required to
overcome a lack of effect of zinc supplements when given alone.
There are concerns, however, about the safety of supplemen-
tation with micronutrients in malaria-endemic areas. In a large
trial among children aged 1–35 months in Pemba [8], supple-
mentation with iron and folic acid increased the incidence of
serious adverse events by 12%, which was assumed to be due to
malaria. Results from a sub-study within this trial suggested that
the overall effect tended to be beneficial in settings with improved
basic care facilities. Also, the increase in adverse events appeared
restricted to those who were iron-replete, whereas supplementa-
tion seemed beneficial in those who were iron-deficient [8,9].
Based on these findings, the World Health Organization now
advocates a policy of restricting iron supplementation to children
with iron deficiency [10]. To strengthen the basis of this
recommendation, the interaction with iron status and the safety
of iron supplements in iron deficient children should be confirmed
in other studies.
Although randomised trials in malaria-endemic areas have
consistently shown that preventive iron supplementation (with or
without other micronutrients) reduces the prevalence of anaemia
[11–15], we have not found reports on its effect on haemoglobin
concentrations during febrile episodes of malaria. By increasing
parasite propagation during such episodes, supplementation may
potentially exacerbate haemolysis. Thus, gains in haemoglobin
concentrations due to supplementation before febrile malaria
attacks may be more than compensated for by greater haemoglo-
bin losses during such episodes. In a study in Papua New Guinean
infants (aged 6–12 months), the decrease in haemoglobin
concentration associated with asymptomatic Plasmodium infection
at two surveys seemed more pronounced among those receiving
iron [16]. By contrast, while supplementation with iron and folic
acid increased rates of cerebral malaria in Pemba, it seemed to
reduce rates of severe anaemia, although the statistical evidence
for this reduction was not strong [8].
The primary aim of our study was to assess the effect of
supplementation with zinc, alone or in combination with other
nutrients, on rates of uncomplicated malaria. Secondary aims were
to compare intervention effects in subgroups pre-defined by age,
presence of parasitaemia, and zinc and iron status at baseline. We
also assessed the effect of multi-nutrient supplementation on
haemoglobin concentrations during febrile malaria episodes.
Methods
Study Population
We conducted the study between February 2008 and March
2009, in a rural area in Handeni District, Tanzania [17,18] where
malaria transmission is intense [19]. The trial protocol (Text S1) and
the CONSORT checklist (Text S2) are available online as
supporting information. The study (ClinicalTrials.gov: NCT0-
0623857) was approved by the Ethical Review Committee of
Wageningen University, The Netherlands and the National Health
Research Ethics Review sub-Committee, Dar es Salaam, Tanzania.
We sought written individual informed consent; parents or primary
caretakers were invited to sign (or thumbprint if illiterate) the
informed consent form witnessed by a member of the community
(who countersigned the form). There were no important changes to
methods during the trial.
Study Design
In this trial with a parallel design, children were randomized to
receive daily supplements with: (a) zinc; (b) both zinc and multi-
nutrients; (c) multi-nutrients without zinc; or (d) placebo. Such a
262 factorial design allows the investigation of interaction between
interventions; in the absence of interaction (i.e., the interventions
act independently), data can be analysed ‘at the margins’ [20], and
the design can ‘achieve two trials for the price of one’: every
participant contributes information to each of the randomized
factors simultaneously [21]. The multi-nutrient supplement
included iron (18 mg as ferrous fumarate), folic acid (93.75 mg),
vitamin A (450 mg, as retinyl palmitate), vitamin B12 (1.17 mg),
vitamin B1 (0.625 mg as thiamine nitrate), vitamin B2 (0.55 mg
riboflavin), copper (340 mg), and vitamin E (6.6 mg as RRR-a-
tocopherol), all of which may have haematinic effects. For
practical reasons, children participating in the study daily received
one standard dose of supplements, regardless of age class. The
amount of iron was set to supply on average 2 mg/kg body
weight/day, as recommended to prevent iron deficiency anaemia
[22]. For the youngest children (6–12 months), this amount was
very close to the RNI under conditions of low bioavailability
(18.6 mg). The average intakes of iron actually achieved were
2.3 mg/kg, 1.7 mg/kg, and 1.3 mg/kg bodyweight, for age classes
6–17, 18–35, and 36–59 months, respectively. Table S1 provides
further details of the composition of the supplements.
Sample Size Calculations
Our aim was to measure a malaria rate reduction by 30%
unambiguously [2], and to exclude the null value from the 95%CI
with a minimum probability of 80%. With an anticipated malaria
incidence in the reference group of 1.05 episodes per child-year,
this required an effective sample size of 142 child-years per group.
It should be noted, however, that the relevance of sample size
calculations to the interpretation of study findings is controversial
[23,24]; specifically, in our study, the incidence actually found in
the placebo group was much higher than originally foreseen. No
interim analyses were foreseen or done.
Recruitment
In four villages, resident children aged 6–60 months were listed,
screened, and enrolled in daily batches until attaining the target
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number (n = 600) in August 2008 (Figure S1). Anthropometric
indices were computed as the average of two measurements taken
on consecutive days. Following a physical examination, venous
blood was collected in EDTA-tubes suitable for trace element
analyses (Becton-Dickinson, Franklin Lakes, NJ, USA). One
aliquot was centrifuged immediately after collection and plasma
stored in liquid nitrogen; a second aliquot was examined by
haematology analyser (Sysmex KX21, Kobe, Japan).
Malaria dipstick tests (CareStart, G0121, Access Bio, Mon-
mouth Jct, NJ) were used to detect lactate dehydrogenase
produced by live P. falciparum or other human Plasmodium species.
This test has a sensitivity of 96% for samples with.50 P. falciparum
parasites/mL, and detects only current parasitaemia [25]. Blood
films were prepared for all children. All children with current
Plasmodium infection, as indicated by a positive result for a dipstick
test, received a therapeutic course of artemether-lumefantrine
upon enrolment so that they were at risk of malaria after a post-
treatment prophylactic period [26] in which lumefantrine levels
exceeded the minimum concentration inhibiting parasite multi-
plication.
Children with height-for-age z-scores.21.5 SD (who are at
lower risk of zinc deficiency) [27], weight-for-height z-score,23
SD, haemoglobin concentration ,70 g/L, those unlikely to
comply with interventions, whose parents/guardians refused
consent, or with signs of severe or chronic disease, were excluded
from participation.
Randomisation and Masking
We used stratified block randomisation to allocate interventions.
A colleague not otherwise involved in the trial used tables with
random numbers to generate the allocation sequence consisting of
randomly permuted blocks with random size (4 or 8) within each
of six strata defined by Plasmodium infection (yes/no infected) and
age class (6–17 months, 18–35 months, and 36–60 months).
Interventions were indicated by colour code on paper slips in
opaque, consecutively numbered envelopes that were prepared in
advance, in excess of the expected number required. A simple
colour code (one colour to distinguish each of the four supplement
types) was used to minimize the possibility of children receiving the
wrong supplements. This code was not revealed to researchers,
field staff, or participants, who therefore did not know who
received what intervention. At the end of each screening day, the
names of eligible children were listed by screening number and
each name was randomly allocated to an intervention by drawing
the next envelope from a box that corresponded to the age- and
malaria-specific stratum for that child.
Supplements, as powder in colour-coded capsules, were
contained in blister packs, and administered orally after suspend-
ing capsule contents in clean water or breast milk. All types of
powder had similar appearance, smell, and taste. At the end of
each screening day, when eligibility had been fully established,
children were individually allocated in order of their screening
number to intervention groups by drawing successive envelopes
from a box corresponding to the infection- and age-specific
stratum for that child. The number of the envelope was then
recorded on a list before the envelope was opened. The
randomisation code was not revealed to researchers, field workers,
or participants until data collection was completed and the
database had been finalised and sent to the Trial Oversight
Committee. The colour of the supplements received by each child
was known to participants and field workers but not by the clinical
outcome assessors.
Follow-up and Case Detection
Community volunteers administered supplements 7 days per
week close to the homes of participating children and reported
daily to field staff, who followed up the same day in cases of non-
compliance. Field staff made regular, unannounced spot checks to
ensure adherence to procedures. Supplementation and follow-up
continued for all children until 12 March 2009, when the trial was
stopped (Figure 1). Because we could not start the study on the
date originally foreseen, we had to stop the trial when running out
of resources, before the planned number of person-years were
accrued, but after the desired number of events had been accrued.
Parents were requested to bring study children to the clinic if
their child developed a fever or became unwell. A clinical officer
was on 24-hour duty and collected medical information on
standardised forms. Axillary temperature was measured using an
electronic thermometer and dipstick tests administered for
children with guardian-reported fever; for those with positive test
results, we prepared two blood films and measured whole-blood
C-reactive protein concentrations using a point-of-care test
(QuikRead, Orion Diagnostica, Espoo, Finland).
In accordance with national guidelines, we treated uncompli-
cated malaria with artemether-lumefantrine (Novartis Pharma,
Basel, Switzerland). This drug combination is highly efficacious
[28,29], and was available free of charge at government health-
facilities but not in local shops. Participating children received free
medical care for common illnesses. Because of the strategic
location of the research clinic, and based on interviews with local
informants, we believe that very few sick participants were brought
to other health facilities or were treated at home.
A second survey, at 251 days (median; 95% reference range:
191–296 days) after enrolment, followed similar procedures.
Laboratory Analyses
Peripheral blood parasite density was determined by microsco-
py; slides with results that were inconsistent with those from the
dipstick test were read twice. Asexual Plasmodium parasites were
counted against at least 200 leukocytes, and density, expressed per
mL of blood, was estimated using an assumed leukocyte density of
8,000/mL. For children with very high densities, parasites were
counted per 2,000 erythrocytes, in which case we used the
estimated erythrocyte count at the time of the episode to
determine the number of parasites per mL. The erythrocyte
density was estimated based on haemoglobin concentration
measured by HemoCue meter, using a linear model describing
the relationship between haemoglobin concentrations and eryth-
rocyte counts as assessed during surveys. Plasma concentrations of
C-reactive protein and ferritin were measured (Meander Medical
Centre, Amersfoort, The Netherlands) on a Beckman Coulter
Unicel DxC880i system according to the manufacturer’s instruc-
tions. Plasma zinc concentrations were determined by inductively-
coupled plasma-mass spectrometry (Varian 820-MS; CV: 9% at
26.8 mM; 13% at 21.25 mM and 13% at 15 mM; n= 32,
V= 10 mL).
Statistical Analysis
Data were analysed following a pre-specified plan, by intention-
to-treat, using SPSS (v15?0 for Windows, SPSS, Chicago, IL,
USA), CIA (v2.1.2) [30] and STATA (v11; College Station, TX,
USA). Compliance was measured as the proportion of children
who consumed .95% of scheduled supplements. Nutritional
status was defined by the presence of iron deficiency (plasma
ferritin concentration ,12 mg/L) [22], zinc deficiency (plasma
zinc concentration ,9.9 mmol/mL) [31] or being stunted (height-
for-age z-score,22 SD).
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The primary outcome, an episode of malaria, was pre-defined
as a positive result for the malaria dipstick test in children with
guardian-reported fever in the previous 24 hours and either: (a)
confirmed fever (axillary temperature $37.5uC), or (b) uncon-
firmed fever with inflammation (whole blood C-reactive protein
concentrations $8 mg/L), separated by at least 14 days from a
previous malaria episode. It has been recommended that only
measured fever should be used to identify malaria cases, and to
exclude cases of unconfirmed fever from the analysis [32]. We
considered this approach would miss many malaria episodes
because temperature can fluctuate strongly over the day and many
fever cases would remain undetected during the relatively short
Figure 1. Flow chart of study recruitment and follow-up. Compliance was measured as the proportion of children who consumed .95% of
scheduled supplements.
doi:10.1371/journal.pmed.1001125.g001
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visit to the health facility. Thus we included inflammation as
additional criterion in the case definition for cases of unconfirmed
fever. In the primary analysis we did not use a parasite density
threshold in the malaria case definition [33,34], because this can
lead to biased estimates of intervention effects when the
interventions affect parasite density [35,36]; in addition, density
estimates can vary greatly within short time spans, and ideally
require leukocyte counts to be determined simultaneously
[35,37,38]. To increase the specificity of malaria case definitions,
Plasmodium-infected participants were treated at baseline to clear
parasitaemia before the start of surveillance. Episodes with pre-
defined parasitaemia thresholds (1,000, 3,000, and 5,000 asexual
parasites/mL) were considered as secondary outcomes. We also
assessed the effect of the intervention on relatively severe episodes
(with parasite densities exceeding 10,000 or 100,000 parasites/mL).
Because we considered a priori a reduction in overall malaria
disease burden of primary public health importance [39,40], our
primary analysis included all malaria events. We used Cox models
with robust estimates of the standard error to account for
correlation between episodes within children and interpreted the
hazard ratio as a proxy for the incidence ratio. We calculated the
percentage reduction (or increase) due to the intervention as
1006(12hazard ratio). Following the analysis plan, we adjusted
for prognostic factors at baseline (age class [6–18 months, 18–35
months, and 36–59 months], Plasmodium infection, mosquito net
use, distance between homestead and clinic, height-for-age z-
score). We evaluated possible interaction between zinc and multi-
nutrients by including an interaction term in the Cox regression
model. We also conducted a pre-specified secondary analysis to
assess the influence on effect estimates of excluding observations in
a 14-day post-treatment prophylactic period. To assess changes in
intervention effect over time, we explored effects on all malaria
episodes within the first 100 days of supplementation versus the
subsequent period. We arbitrarily defined a cut-point of 100 days
because this period covered almost half of all episodes, and
adjusted for baseline factors as described above. We similarly
explored intervention effects within the first 50 days.
In a secondary analysis we assessed intervention effects on time-
to-first malaria episode using Kaplan-Meier analysis, and
compared hazard rates of first episodes using Cox regression.
After we concluded that there was no evidence for interaction
between zinc and multi-nutrients on malaria rates, we conducted
pre-specified subgroup analyses (all events; unadjusted) to explore
to what extent the magnitude of marginal intervention effects on
malaria frequency depended on age class, presence of parasitae-
mia, and zinc and iron status at baseline, by including (for each
factor in turn) interaction terms in the Cox regression models.
Lastly, we explored whether differences in intervention effects
between subgroups were consistent when using higher parasite
density cut-offs.
Results
Of 1,029 screened children, 662 had height-for-age z-
scores#21.5 SD; of these, 612 were eligible and randomised.
Twenty children (3%) did not complete the trial: three died, two
were withdrawn by parents, and 15 emigrated from the area
(Figure 1). Another two children discontinued the intervention but
were available for follow-up. Compliance was high (96%) and
similar in all four groups.
Groups were similar in baseline characteristics except that there
were slightly more boys and zinc-deficient children in the multi-
nutrient group (Table 1). The prevalence of zinc deficiency was
67% overall, and 60% in those without inflammation; the
prevalence of zinc deficiency was dramatically reduced by zinc
supplementation, whether given alone or with other micronutri-
ents (Table 2).
There were 3,268 clinic visits during the study period, of which
2,462 (75%) were accompanied by guardian-reported fever. Of
2,462 episodes of reported fever, 1,618 (66%) were accompanied
by Plasmodium infection as detected by dipstick test; for 46 children
parasitaemia was not accompanied by confirmed fever or
inflammation. Hence, 1,572 episodes classified as malaria: 1,499
(95%) due to P. falciparum and 73 (5%) due to other Plasmodium
species. The incidence of malaria was 3.0 events/child-year. There
were 1,408, 1,314, 1,248, 1,119, and 263 episodes with densities
exceeding 1,000, 3,000, 5,000, 10,000, and 100,000 parasites/mL,
respectively. Of all hospital admissions (68), almost half (30 cases
occurring in 27 children) were due to malaria: five were admitted
for life-threatening disease (respiratory distress or prostration; none
had neurological manifestations); 25 lived far from the dispensary,
and the clinician referred them as a precaution (18 for
haemoglobin concentrations ,60 g/L without respiratory distress
or dehydration and seven for other reasons). There were no
episodes of cerebral malaria.
Primary Analysis: Effects on All Episodes of Malaria
Compared to placebo, there was no evidence of a meaningful
effect of either zinc or multi-nutrients alone on the incidence of
malaria. The hazard ratio for all episodes of malaria by zinc was
0.99; 95% CI 0.82–1.18 (adjusted model, as compared to placebo).
Thus for zinc, the lower limit of the confidence interval is
compatible with a reduction in incidence of all episodes of malaria
of 18% only. The hazard ratio for all episodes of malaria by multi-
nutrients (as compared to placebo) was 1.04, 95% CI 0.87–1.23
(adjusted model; see Table 3). Incidence of all episodes of malaria
was slightly higher in the group that received both zinc and multi-
nutrients, as compared to placebo (HR 1.14, 95% CI 0.96–1.35),
but there was no evidence of an interaction between zinc and
multi-nutrients in their effects on malaria incidence (interaction
ratio 1.10, 95% CI 0.84–1.43). In the remainder of this paper, we
will assume that the interventions acted independently, and report
marginal analyses accordingly [20]. Thus analysed, there was no
evidence that zinc supplementation affected malaria rates
(adjusted HR: 1.04, 95% CI 0.93–1.18), whereas supplementation
with multi-nutrients seemed to slightly increase malaria rates
(adjusted HR 1.10, 95% CI 0.97–1.24). Excluding observations for
14 days post-treatment or restricting the analysis to P. falciparum
cases did not change our conclusions (unpublished data).
Secondary Analyses: Effects of Zinc on Malaria Rates
Likewise, when using different case definitions, we found no
evidence that zinc protected against malaria when episodes were
defined using density thresholds of 1,000 parasites/mL (HR 1.02,
95% CI 0.90–1.16), 3,000 parasites/mL (HR 1.01, 95% CI 0.88–
1.17) or 5,000 parasites/mL (HR 1.00, 95% CI 0.87–1.16), or that
zinc influenced the incidence or time-to-first episode of malaria
(Table 3; Figure 2). Nor was there evidence that rates of episodes
with parasite densities exceeding 10,000 parasites/mL and 100,000
parasites/mL were reduced by zinc (HR 1.00, 95% CI 0.87–1.16
and HR 1.19, 95% CI 0.89–1.58, respectively).
Lastly, we found no evidence that zinc protected against malaria
after 100 days of supplementation (HR 1.01, 95% CI 0.86–1.18),
or that the intervention effect depended on the duration of
supplementation (100 days or less versus more than 100 days,
p = 0.29), or by any of the pre-specified baseline factors (age class,
Plasmodium infection, height-for-age z-score or zinc status) or by sex
(unpublished data).
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Secondary Analyses: Effects of Multi-nutrients on Malaria
Rates
There was some indication that the effect of multi-nutrients
on malaria rates decreased over time: when analysis was limited
to the first 100 days of supplementation, the hazard ratio was
1.17 (95% CI 1.02–1.34), and in the first 50 days 1.23 (95% CI
1.02–1.50), but the statistical evidence for a change in the effect
of multi-nutrients over time was weak (p-value for the change in
effect 0.10 and 0.17 with time entered as continuous or
categorical [, or $100 days] variable). When analysis was
limited to the first or only episode, malaria rates were greater in
those who received multi-nutrients (HR 1.29, 95% CI 1.08–
1.54), and the median time to the first episode of malaria was 54
days for children receiving multi-nutrients, compared to
72 days for those without (p = 0.01; Tarone-Ware test,
Figure 2).
When analysing the data by iron status at baseline, multi-
nutrient supplementation appeared to increase the overall number
of malaria episodes by 41% (95% CI 9%–82%) in children with
iron deficiency, whereas there was no evident effect in their iron-
replete peers (Figure 3; p-value for difference in effect 0.01). For
episodes with densities .10,000 and .100,000 parasites/mL,
similar effect modification was observed, whereby the increase in
rates remained consistently and, with similar magnitude, restricted
to children with iron deficiency (Figure S2).
The prevalence of iron deficiency at baseline decreased rapidly
with age (38%, 20% and 5% in children aged 6–17 months, 18–35
months, and 36–60 months, respectively; p,0.001; corresponding
values in those without inflammation: 45%, 28%, and 7%; p,0.001).
As with initial iron status, age strongly modified the effect of multi-
nutrients on malaria incidence (Figure 3). Contrasts between age-
specific effects on malaria rates increased when defining episodes with
higher parasite density cut-offs (Figure S3). For episodes with hyper-
parasitaemia (.100,000 parasites/mL), multi-nutrients increased
rates by 54% (95% CI 1%–137%) in the youngest children, but
reduced rates by 58% (95% CI23% to282%) in the eldest (p-value
for interaction: 0.006), with an overall neutral effect.
Secondary Analyses: Effect of Multi-nutrients on
Haemoglobin Concentrations
Analysis of haemoglobin concentrations at the second survey
(when virtually all children were symptom-free) showed that the
youngest children and those with iron deficiency at baseline
responded most to multi-nutrient supplementation (8.4 g/L, 95%
Table 1. Baseline characteristics of study participants, by intervention group.
Zinc
Multi-nutrients without
Zinc Multi-nutrients with Zinc Placebo
n 153 155 151 153
Sex M/F [n/n] 46%/54% [70/83] 56%/44% [87/68] 44%/56% [66/85] 50%/50% [76/77]
Age class
6–17 months 24% [36] 23% [36] 24% [36] 24% [36]
18–35 months 36% [55] 36% [55] 34% [51] 35% [54]
36–59 months 41% [62] 41% [64] 42% [64] 41% [63]
Plasmodium infectiona 43% [66] 41% [64] 44% [67] 44% [68]
Height-for-age, z-score 22?3660?69 22?5060?69 22?3960?71 22?4560?69
Inflammationb 34% [52] 33% [51] 34% [51] 31% [47]
Zinc deficiencyc
All children 63% [97] 71% [110] 70% [105] 65% [100]
Without inflammationd 58% [59] 65% [68] 59% [59] 60% [64]
Haemoglobin concentration, g/L 101?8612?6 102?7612?8 103?8612?7 102.8612?7
Anaemiae 75% [114] 65% [100] 68% [103] 65% [100]
Iron deficiencyf
All children 16% [25] 18% [28] 20% [30] 19% [28]
Without inflammationd 23% [23] 24% [25] 24% [24] 24% [25]
Iron deficiency anaemia
All children 12% [18] 12% [19] 15% [23] 14% [21]
Without inflammationd 16% [16] 16% [17] 18% [18] 18% [19]
Distance from homestead to dispensary, kmg 3?6662?31 3?5262?06 3?5462?07 3?6063?38
Mosquito net useh 32% [48] 36% [55] 30% [45] 31% [46]
Mean 6 SD, % [n] or median (25- and 75-percentiles) unless indicated otherwise.
aAs indicated by a positive result for pLDH-based dipstick test (see text).
bPlasma C-reactive protein concentration $8 mg/L.
cPlasma zinc concentration ,9.9 mmol/L.
dn = 101, 104, 100 and 106, respectively (five missing values for plasma ferritin concentration).
eHaemoglobin concentration ,110 g/L.
fPlasma ferritin concentration ,12 mg/L (six missing values).
gMeasured as the crow flies, based on global positioning data.
hData missing for 11 children.
doi:10.1371/journal.pmed.1001125.t001
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CI 4.2 212.5 g/L and 8.7 g/L, 95% CI 5.3–12.2 g/L, respec-
tively; Figure 4). Similar beneficial effects were found at time of the
first malaria episode: multi-nutrients increased haemoglobin
concentrations by 6.5 g/L (95% CI 1.2–11.9 g/L) in children
with iron deficiency, while no marked effect was apparent in those
who were iron replete (22.1 g/L, 95% CI 24.7 to 0.5 g/L;
Table 2. Intervention effects on indicators of nutritional status, inflammation and malaria at the second survey.
Zinc Micronutrients without Zinc Micronutrients with Zinc Placebo
Estimate Effecta Estimate Effecta Estimate Effecta Estimate
nb 149 151 148 150
Plasmodium infectionc 33% [50] 5% (25% to 15%) 34% [52] 6% (24% to 16%) 33% [49] 5% (25% to 15%) 28% [42]
Inflammationd 35% [54] 2% (29% to 12%) 25% [38] 210% (220% to 1%) 33% [50] 21% (212% to 10%) 34% [52]
Plasma zinc concentration,
mmol/L
16.0 [6.2] 6.4 (5?4 to 7?3) 9.6 [2.6] 0.0 (20.9 to 0.9) 13.5 [4.2] 3.9 (2.9 to 4.8) 9.6 [2.7]
Zinc deficiencye
All children 11% [16] 252% (260% to
242%)
57% [89] 25% (215% to 6%) 22% [33] 240% (250% to
230%)
62% [95]
Without inflammation 4% [4] 258% (267% to
246%)
47% [53] 215% (227% to 21%)20% [19] 243% (254% to
229%)
62% [60]
Haemoglobin concentration,
g/L
103.7 [11.8] 20.4 (23?0 to 2?3) 106.6 [10.7] 2.6 (0?0 to 5?2) 107.5 [11.4] 3.5 (0?8 to 6?1) 104.0 [11.9]
Anaemiaf 65% [100] 1% (210% to 11%) 50% [77] 215% (226 to 24%) 52% [79] 212% (223% to 21%)65% [99]
Plasma ferritin concentrationg
All children 31.1 [0.03] 21.6 (26?8 to 4?8) 57.1 [0.03] 24.5 (14?8 to 36?2) 57.2 [0.03] 24.6 (14?8 to 36?3) 32.6 [0.03]
Without inflammation 23.2 [0.04] 21.2 (25?5 to 4?2) 43.9 [0.03] 19.5 (11?3 to 28?6) 51.1 [0.03] 26.7 (17?5 to 38?1) 24.4 [0.04]
Iron deficiencyh
All children 11% [17] 22% (29% to 6%) 1% [1] 212% (219% to 27%) [0] 213% (219% to 28%)13% [20]
Without inflammation 17% [16/95] 23% (214% to 8%) 1% [1/
113]
220% (229% to
212%)
[0/98] 220% (229% to
212%)
20% [19/97]
Effects in the three groups receiving zinc alone, multi-nutrients without zinc and zinc plus multi-nutrients, as compared to placebo. Estimates indicate prevalence values
[n], arithmetic mean [SD], or geometric mean [SE].
aDifference relative to placebo (95%CI), for prevalences computed using Newcombe’s method [30].
bDifferences between numbers reported and numbers randomised are due to drop-outs; percentages are computed with the number of randomised children in the
denominator.
cAs indicated by a positive result for pLDH-based dipstick test (see text).
dPlasma C-reactive protein concentration $8 mg/L.
ePlasma zinc concentration ,9.9 mmol/L.
fHaemoglobin concentration ,110 g/L.
gGeometric mean.
hPlasma ferritin concentration ,12 mg/L [22].
doi:10.1371/journal.pmed.1001125.t002
Table 3. Incidence rates by intervention group and intervention effects on malaria rates, relative to placebo.
Event Zinc Multi-nutrients without Zinc Multi-nutrients with Zinc Placebo
All episodes of malaria (1,572
cases)
Incidence 2.89 [378/130.8] 2.95 [393/133.2] 3.26 [423/129.7] 2.87 [378/131.9]
HR, crude 1.01 (0.87 to 1.16) 1.03 (0.89 to 1.19) 1.14 (0.99 to 1.31) 1.0 (Reference)
HR, adjusteda 0.99 [0.82 to 1.18] 1.04 [0.87 to 1.23] 1.14 [0.96 to 1.35] 1.0 (Reference)
First episode of malaria (507
cases)
Incidence 2.71 [124/45.8] 3.27 [133/40.7] 3.37 [129/38.3] 2.52 [121/47.9]
Incidence ratio 1.08 (0.83 to 1.38) 1.29 (1.01 to 1.65) 1.33 (1.04 to 1.71) 1.0 (Reference)
HR, adjusteda 1.12 (0.86 to 1.44) 1.35 (1.05 to 1.73) 1.38 (1.07 to 1.77) 1.0 (Reference)
Numbers in brackets indicate [no. events/no. person-year] or (95% CIs).
aHazard ratio (HR), adjusted for age class (18–35 months and 36–59 months), presence of Plasmodium infection, mosquito net use (binary variable), distance between
homestead and clinic (continuous variable), and height-for-age z-score (continuous variable) at baseline.
doi:10.1371/journal.pmed.1001125.t003
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Figure 2. Effect of zinc (panel A) or multi-nutrients (panel B) on time to first malaria episode. Marginal group comparisons (Kaplan-Meier
analysis), with p-values obtained by Tarone-Ware test. Values below each panel indicates the number of children at risk.
doi:10.1371/journal.pmed.1001125.g002
Micronutrient Supplementation and Malaria
PLoS Medicine | www.plosmedicine.org 8 November 2011 | Volume 8 | Issue 11 | e1001125
difference in effect: 8.6 g/L, 95% CI 2.7–14.6 g/L; p-value
0.004); (Figure 5). Similar patterns were observed for the
intervention effects on haemoglobin concentrations during the
second malaria episode (unpublished data).
Discussion
Despite a high prevalence of zinc deficiency, excellent
compliance, and few drop-outs, we found no evidence from this
trial that preventive zinc supplementation, alone or with multi-
nutrients, reduced rates of febrile attacks of malaria. In the
primary analysis, there was no evidence that multi-nutrients
influenced malaria rates, but results from a secondary analysis
suggest that multi-nutrient supplementation may have increased
the incidence of first malaria episodes by approximately 30%. The
effect of supplementation on overall malaria rates seemed to vary
with iron status at baseline: among children with iron deficiency,
multi-nutrients increased rates of malaria episodes by 41%, while
they had no effect in those who were iron replete. This difference
in effect was unlikely to have been observed by chance (p = 0.01).
One limitation of our study is that supplements were colour-
coded and not in packs labelled with individual identity numbers.
During the field work, however, we received no indication that
participants or field staff discovered who received what interven-
tion, or that participants favoured a particular type of supplement.
It should be noted also that the clinical outcome assessors were
blinded to what intervention had been assigned to individual
children. HIV infection was not assessed in our study but is
unlikely to have confounded its results: the prevalence of HIV
infection in this paediatric population is probably below 5% and,
due to the randomisation process, marked imbalances in HIV
infection at baseline are unlikely.
By excluding children with height-for-age z-score.21.5 SD,
the children enrolled in our trial probably were more zinc deficient
than the general population from which they were sampled. Thus
the effect on malaria rates that could potentially be attained in the
general population, without this exclusion criterion, is probably
smaller than that reported here. Two previous trials indicated that
zinc can protect against malaria. The Gambian trial [2] was not
designed to assess this association, and episodes were recorded
through routine clinical procedures. In Papua New Guinea, zinc
reduced the incidence of febrile episodes with parasitaemia
$9,200/mL and $100,000/mL by 38% (95% CI 3%–60%) and
69% (95% CI 36%–87%), respectively [3]. Both studies were
smaller than our study (91 cases of P. falciparum malaria in Papua
New Guinea, as compared to 1,499 in our study). It seems unlikely
that discrepancies with our findings are explained by differences in
access to health care and a differential effect on rates of severe
malaria: even with episodes with parasitaemia $100,000/mL, our
confidence intervals (Table 3) are incompatible with the
magnitude of the protective effect reported from Papua New
Guinea. In addition, the overall and malaria-specific mortality
reduction found in Pemba (7% and 10%, respectively) [41], seems
inconsistent with the 69% reduction in episodes with parasitaemia
$100,000/mL that was reported from Papua New Guinea. The
intensity of malaria transmission in Papua New Guinea was much
lower than in Burkina Faso, Pemba, or our study, raising the
question of whether zinc affords protection only in populations
with low acquired immunity. The absence of an age-dependent
decrease in efficacy of zinc supplementation in our study makes
this unlikely. Thus the divergent results from Papua New Guinea
may be due to unknown differences in host, parasite, or
environmental factors that predict the response to zinc.
Figure 3. Effect of multi-nutrient supplementation on malaria rates, by iron status and age class. Malaria with case definition as pre-
defined in the analysis plan. Values on the right indicate crude hazard ratios (95% CIs); p-values for differences in intervention effects between
subgroups (with age class entered on an ordinal scale). Initial iron status was defined as iron-deficient (black diamond; plasma ferritin concentration
,12 mg/L, n = 111) or iron replete (white diamond; plasma ferritin concentration $12 mg/L, without inflammation; n = 312). In the analysis, we
excluded children in whom iron status was uncertain (plasma ferritin concentration $12 mg/L, with inflammation); hence analyses are restricted to
423 subjects. Adjustment for distance between homestead and dispensary, height-for-age z-scores, mosquito net use, and Plasmodium infection at
baseline led to similar estimates (unpublished data).
doi:10.1371/journal.pmed.1001125.g003
Micronutrient Supplementation and Malaria
PLoS Medicine | www.plosmedicine.org 9 November 2011 | Volume 8 | Issue 11 | e1001125
Because malaria parasites are transmitted through mosquito
bites, they bypass epithelial barriers that form the first line of
defence against pathogens that cause diarrhoea and respiratory
infections. Zinc is known to play a critical role in maintaining
epithelial barrier function [42–46]. In vitro studies using Caco-2
cells suggest that tight junctions between intestinal epithelial cells
have impaired function in zinc deficiency [46], whilst morpho-
logical studies and findings from a zinc supplementation trial in
Bangladeshi children with diarrhoea suggest that zinc deficiency
adversely affects intestinal permeability [47,48]. The protective
effect of zinc against diarrhoea and respiratory infections, as
compared to the absence of such an effect against malaria, suggest
that this nutrient primarily acts by strengthening barrier function
rather than through immunity.
Our results also suggest that an increase in overall malaria rates
may have occurred in children with iron deficiency. Subgroup
Figure 4. Effect of multi-nutrients on haemoglobin concentration at the second survey, by iron status and age class. Top:
haemoglobin concentrations, by supplementation group. Bottom: effects of multi-nutrients on haemoglobin concentrations. Left: By initial iron
status. Right: By age class. Line bars indicate 95% CIs (only upper half of the interval indicated in top panel). Analysis based on 598 children. All
estimates are adjusted for standardized haemoglobin concentrations at baseline. p-Values indicate interaction between age class or iron status and
intervention effects on haemoglobin concentration.
doi:10.1371/journal.pmed.1001125.g004
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analyses should generally be interpreted with caution [49]. On one
hand, we did not specify interactions between multi-nutrient
supplementation and iron status a priori, and the direction of the
subgroup effect is in contrast with the findings previously obtained
in the Pemba sub-study with iron and folic acid [8]. On the other
hand, the difference in effects of multi-nutrients between children
with and without iron deficiency was large, the statistical evidence
for effect modification was strong and consistent for other malaria-
related outcomes (haemoglobin concentration and malaria
episodes with higher parasite densities).
Because the effect of multi-nutrient supplementation on malaria
in our trial depended on initial iron status, it would seem most
likely that this was caused by iron, and not by other nutrients in
the supplement. Diverse lines of evidence suggest that, of all the
micronutrients, iron is the most critical mediator of host–pathogen
interactions [50], and our findings build on existing evidence
Figure 5. Effect of multi-nutrients on haemoglobin concentration during the first malaria episode, by iron status and age class. Top:
haemoglobin concentrations, by supplementation group. Bottom: effects of multi-nutrients on haemoglobin concentrations. (A and B) By initial iron
status. C and D) By age class. Line bars indicate 95% CIs (only upper half of the interval indicated in top panel). Analysis is based on 507 episodes. All
estimates are adjusted for standardized haemoglobin concentrations at baseline. Further adjustment for time between start of intervention and
episode led to virtually identical estimates. p-Values indicate interaction between age class or iron status and intervention effects on haemoglobin
concentration.
doi:10.1371/journal.pmed.1001125.g005
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suggesting that supplementation with iron can increase malaria
risk [8,51–54].
In their report of the findings from the Pemba sub-study [8], the
authors were cautious in their interpretation of the subgroup
effect, stating that their results suggested that supplementation
with iron and folic acid is beneficial in children with iron
deficiency, but unsafe in those who are iron-replete. Based on
these findings, an expert group convened by the World Health
Organization recommended that iron supplements should be
administered routinely to iron-deficient infants in settings with
adequate access to anti-malarial treatment [10]. Unfortunately,
our findings contradict those from the Pemba study, and thereby
cast doubt on the assumption that iron is safe in iron-deficient
children. In the Pemba study, iron deficiency (found in 75% of
children) was defined by elevated molar ratios of zinc protopor-
phyrin and haem. Although to their credit, ZPP:H ratios react
more slowly to inflammation than plasma ferritin concentrations,
elevated ratios may occur due to (longstanding) inflammation,
(asymptomatic) Plasmodium infection, and thalassaemia (Veene-
mans, unpublished data), and hence falsely indicate iron
deficiency. Plasma ferritin concentration below 12 mg/L as
indicator of iron deficiency may fail to detect deficient children
in the presence of inflammation, but it is a highly specific marker
of iron deficiency, probably more so than the ZPP:H ratio.
We speculate that iron may have enhanced parasite prolifera-
tion specifically in children with iron deficiency, because iron
absorption in this subgroup is more efficient and thus may lead to
transient production of non-transferrin bound iron [55–57], which
may act as a nutritional source and favour the proliferation of
Plasmodium parasites [10]. Evidence in support of this hypothesised
mechanism is, however, lacking. In addition, children with a low
plasma ferritin concentration are probably free of inflammation
and likely to absorb iron rapidly. Because children with iron
deficiency were substantially younger, the difference in effect
between subgroups of iron-replete and -deficient children may also
(partly) have been mediated by the lack of protective immunity in
these younger children, and the higher dose of supplemental iron
per kilogram of bodyweight. It seems plausible that the magnitude
of potential adverse effects of iron is determined by a combination
of the host’s immune status, dose of iron per kg bodyweight, and
the amount of iron absorbed. The qualitative interaction with age
and iron status as observed in our study emphasizes the need for
trials to take these into account in the analysis, as overall estimates
may tend towards a neutral effect [58].
We found no support for our initial hypothesis that, at the time of
malaria episodes, haemoglobin concentrations would be lower in
children receiving multi-nutrients. In fact, young children with iron
deficiency (who were most vulnerable to declines in haemoglobin)
were better able to maintain their haemoglobin concentration when
they received multi-nutrients. The critical issue remains whether the
benefits of higher haemoglobin concentrations during acute malaria
and thus the expected reduced risk of severe malarial anaemia, on
one hand, outweigh the potential risk of severe disease manifesta-
tions that can be associated with an increased frequency of malaria,
on the other hand. Access to primary care facilities may be a critical
factor determining this balance, and in the absence of early
treatment, the youngest children with iron deficiency may be a
vulnerable subgroup.
The estimated amount of iron absorbed from our supplement is
close to that absorbed from multi-nutrient mixes used for home
fortification [59–61]. Our data question the safety of supplying
these mixes to vulnerable populations, particularly in settings with
poor malaria prevention, but even in conditions where access to
diagnosis and therapy for malaria is excellent, as in our study.
In conclusion, when results from all trials are considered
together, there is no evidence that zinc interventions can reduce
the burden of malaria in African children. We have presented
evidence that multi-nutrient supplementation may increase the
risk of malaria in children with iron deficiency, strengthening
earlier concerns about the safety of multi-nutrient supplementation
in malaria-endemic areas, even in settings with good access to
health care and appropriate treatment. Similar risks may apply to
home fortification in such settings. Although safety may be
improved by modifying the formulation of supplements (in
particular by reducing the iron dose) implementing multi-nutrient
supplementation or home fortification as a public health measure
should be carefully monitored until this has been demonstrated.
The World Health Organization recommendation that iron
should be supplemented to iron-deficient children needs recon-
sideration, not because we claim that our study provides
conclusive evidence that targeting this group is unsafe, but
because the current guideline is based on weak evidence from a
single study that is contradicted by our findings using highly
specific markers of iron deficiency.
Supporting Information
Figure S1 Participant flow over time. The black line
indicates the cumulative number of children in the trial.
Recruitment started in February 2008 (day 0) and was completed
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Figure S2 Effect of multi-nutrient supplementation on
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between iron-deficient and iron-replete children were 0.02, 0.01
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Editors’ Summary
Background. Malaria is a serious global public-health
problem. Half of the world’s population is at risk of this
parasitic disease, which kills a million people (mainly children
living in sub-Saharan Africa) every year. Malaria is transmitted
to people through the bites of infected night-flying
mosquitoes. Soon after entering the human body, the
parasite begins to replicate in red blood cells, bursting out
every 2–3 days and infecting more red blood cells. The
presence of the parasite in the blood stream (parasitemia)
causes malaria’s characteristic recurring fever and can cause
life-threatening organ damage and anemia (insufficient
quantity of red blood cells). Malaria transmission can be
reduced by using insecticide sprays to control the
mosquitoes that spread the parasite and by avoiding
mosquito bites by sleeping under insecticide-treated bed
nets. Effective treatment with antimalarial drugs can also
reduce malaria transmission.
Why Was This Study Done? One reason why malaria kills
so many children in Africa is poverty. Many children in Africa
are malnourished, and malnutrition—in particular, insuffi-
cient micronutrients in the diet—impairs the immune
system, which increases the frequency and severity of
many childhood diseases. Micronutrients are vitamins and
minerals that everyone needs in small quantities for good
health. Zinc is one of the micronutrients that helps to
maintain a healthy immune system, but zinc deficiency is
very common among African children. Zinc supplementation
has been shown to reduce the burden of diarrhea in
developing countries, so might it also reduce the burden of
malaria? Unfortunately, the existing evidence is confusing—
some trials show that zinc supplementation protects against
malaria but others show no evidence of protection. One
possibility for these conflicting results could be that zinc
supplementation alone is not sufficient—supplementation
with other micronutrients might be needed for zinc to have
an effect. In this randomized trial (a study that compares the
effects of different interventions in groups that initially are
similar in all characteristics except for intervention), the
researchers investigate the effect of supplementation with
zinc alone and in combination with other micronutrients on
the rate of uncomplicated (mild) malaria among children
living in Tanzania.
What Did the Researchers Do and Find? The researchers
enrolled 612 children aged 6–60 months who were living in a
rural area of Tanzania with intense malaria transmission and
randomly assigned them to receive daily oral supplements
containing zinc alone, multi-nutrients (including iron)
without zinc, multi-nutrients with zinc, or a placebo (no
micronutrients). Nutritional indicators (including zinc
concentrations in blood plasma) were assessed at baseline
and 6–10 months after starting the intervention. During the
study period, there were 1,572 malaria episodes. The
incidence of malaria in all four intervention groups was
very similar (about three episodes per child-year), and there
was no evidence that multi-nutrients influenced the effect of
zinc (or vice versa). Moreover, none of the supplements had
any effect on malaria rates when compared to the placebo,
even though the occurrence of zinc deficiency was strongly
reduced by zinc supplementation. In a secondary analysis in
which they analyzed their data by iron status at baseline, the
researchers found that multi-nutrient supplementation
increased the overall number of malaria episodes in
children with iron deficiency by 41%, whereas multi-
nutrient supplementation had no effect on the number of
malaria episodes among children who were iron-replete at
baseline.
What Do These Findings Mean? In this study, the
researchers found no evidence that zinc supplementation
protected against malaria among young children living in
Tanzania when given alone or in combination with other
multi-nutrients. However, the researchers did find some
evidence that multi-nutrient supplementation may increase
the risk of malaria in children with iron deficiency. Because
this finding came out of a secondary analysis of the data, it
needs to be confirmed in a trial specifically designed to
assess the effect of multi-nutrient supplements on malaria
risk in iron-deficient children. Nevertheless, it is a potentially
worrying result because, on the basis of evidence from a
single study, the World Health Organization currently
recommends that regular iron supplements be given to
iron-deficient children in settings where there is adequate
access to anti-malarial treatment. This recommendation
should be reconsidered, suggest the researchers, and the
safety of multi-nutrient mixes that contain iron and that are
dispensed in countries affected by malaria should also be
carefully evaluated.
Additional Information. Please access these Web sites via
the online version of this summary at http://dx.doi.org/10.
1371/journal.pmed.1001125.
N Information is available from the World Health Organiza-
tion on malaria (in several languages), on micronutrients,
and on zinc deficiency; the 2010 World Malaria Report
provides details of the current global malaria situation
N The US Centers for Disease Control and Prevention provide
information on malaria (in English and Spanish), including
a selection of personal stories about malaria
N Information is available from the Roll Back Malaria
Partnership on the global control of malaria and on
malaria in Africa
N The Malaria Centre at the UK London School of Hygiene &
Tropical Medicine develops tools, techniques, and knowl-
edge about malaria, and has a strong emphasis on
teaching, training, and translating research outcomes into
practice
N The Micronutrient Initiative, the Global Alliance for
Improved Nutrition, and the Flour Fortification Initiative
are not-for-profit organizations dedicated to ensuring that
people in developing countries get the minerals and
vitamins they need to survive and thrive
N The International Zinc Nutrition Consultative Group
(iZiNCG) is a non-profit organization that aims to promote
and assist efforts to reduce zinc deficiency worldwide,
through advocacy efforts, education, and technical assis-
tance
N MedlinePlus provides links to additional information on
malaria (in English and Spanish)
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